A new RNA-interference based strategy is associated with mild beneficial effects in patients with heart failure due to cardiac amyloidosis

Eur Heart J. 2024 Apr 1;45(13):1102-1103. doi: 10.1093/eurheartj/ehae015.

Authors

Leonarda Galiuto^{1

2}, Massimo Volpe^{2

3}

Affiliations

¹ Cardiology Unit, Cardiothoracic Department, Sant' Andrea University Hospital Rome, Italy.
² Department of Clinical and Molecular Medicine, Sapienza University of Rome, Via di Grottarossa, 1035-1039, Rome 00189, Italy.
³ IRCCS San Raffaele Roma, Italy.

PMID: 38240583
DOI: 10.1093/eurheartj/ehae015

No abstract available

MeSH terms

Amyloidosis* / complications
Cardiomyopathies* / complications
Cardiomyopathies* / genetics
Heart Failure* / complications
Humans
RNA

Substances

RNA